Research Paper Volume 13, Issue 1 pp 181—193
The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance
Figure 5. Impacts of neutralization of ICAM-1 in vitro and in vivo. (A, B) Neutralization of ICAM-1 did not affect rituximab and other anti-CD20 antibodies mediated CMC and ADCC in rituximab sensitive cell lines. (C) MTT assay showed that downregulation of ICAM-1 could cause resistance of rituximab. (D) Kaplan-Meier analyses showing the survival curves of neutralization of ICAM-1 alone and in combination with rituximab in vivo. (*P<0.05, **P <0.01, ***P <0.001,****P <0.0001).